Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
| ▸ | GUSB | P08236 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11302849 | 0.93 | ALDH1A1 (0.51) | TSHRUSP2NPSR1CTSDGUSB | |
| SCHEMBL1384956 | 0.88 | ALDH1A1 (0.56) | TSHRUSP2NPSR1CTSDGUSB | |
| SCHEMBL2578815 | 0.87 | CTSD (0.51) | TSHRUSP2NPSR1CTSDGUSB | |
| SCHEMBL2575692 | 0.86 | CTSD (0.58) | TSHRUSP2NPSR1CTSDGUSB | |
| SCHEMBL2581454 | 0.84 | KDM4E (0.69) | TSHRNPSR1CTSDGUSBPOLB | |
| SCHEMBL1385523 | 0.83 | KDM4E (0.71) | TSHRCTSDGUSBBCHEKDM4E | |
| SCHEMBL11891125 | 0.81 | KDM4E (0.55) | TSHRBCHEKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL23118938 | 0.80 | KDM4E (0.53) | TSHRBCHEKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2584579 | 0.80 | KDM4E (0.58) | TSHRBCHEKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL18791198 | 0.79 | ALDH1A1 (0.59) | TSHRUSP2NPSR1BCHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | claimed |
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | BASILEA PHARMACEUTICA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20190010536-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | BASILEA PHARMACEUTICA AG (CH) | 2019-01-10 | — | — | US | disclosed |
| US-10067120-B2 | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-10006078-B2 | Use of phospho-Akt as a biomarker of drug response | BASILEA PHARMACEUTICA AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-9995754-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-06-12 | — | — | US | disclosed |
| US-9970938-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-05-15 | — | — | US | disclosed |
| US-20170122934-A1 | USE OF ACETYLATED TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2017-05-04 | — | — | US | disclosed |
| EP-2691533-B1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | BASILEA PHARMACEUTICA AG (CH) | 2017-04-05 | — | — | EP | disclosed |
| US-20130345263-A1 | USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2013-12-26 | — | — | US | disclosed |
| EP-2666015-A1 | USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012130887-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | BASILEA PHARMACEUTICA AG (CH) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012098208-A1 | USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-RE42890-E1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-7385061-B2 | 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-3-yl]-N-(2-cyanoethyl)-amine; treatment of neoplastic and autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2008-06-10 | — | — | US | disclosed |
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20070043061-A1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG | 2007-02-22 | — | — | US | disclosed |
| EP-1636215-A1 | FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004103994-A1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | AKT3, AKT1S1, AKT2 | TSHR 818/4885USP2 3382/4885NPSR1 2434/4885 |
| US-20190010536-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | AKT3, AKT1S1, AKT2 | TSHR 818/4885USP2 3382/4885NPSR1 2434/4885 |
| US-10067120-B2 | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | TUBB1, TUBB, TUBB6 | TSHR 4281/4885USP2 2022/4885NPSR1 4358/4885 |
| US-20130345263-A1 | USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | STMN1, STMN2, MYADM | TSHR 3734/4885USP2 1557/4885NPSR1 3914/4885 |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BUB1B, BUB1, BUB3 | TSHR 2717/4885USP2 483/4885NPSR1 2386/4885 |
| US-10006078-B2 | Use of phospho-Akt as a biomarker of drug response | AKT3, AKT2, AKT1S1 | TSHR 3124/4885USP2 2993/4885NPSR1 2588/4885 |
| US-20070043061-A1 | Furazanobenzimidazoles | FOXO1, CYP2F1, OXER1 | TSHR 1025/4885USP2 3733/4885NPSR1 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.